As COVID-19 continues to expand across the globe, more pharmaceutical companies are hitting the brakes on clinical trials as part of an effort to ease the burden on doctors and facilities needed to treat patients combating the disease.
The U.S. Food and Drug Administration has a busy week of possible drug approvals on the regulatory agency’s calendar, including Celgene’s ozanimod for relapsing forms of multiple sclerosis.
Galectin Therapeutics Inc., a leader in the field of NASH therapeutics, announced the appointment of Pol F. Boudes, M.D. to the position of Chief Medical Officer.
The U.S. Food and Drug Administration granted Fast Track designation for the clinical-stage biopharmaceutical company Inventiva’s lead product candidate, lanifibranor, for the treatment of non-alcoholic steatohepatitis (NASH).
Enanta Pharmaceuticals Inc. announced top-line results from the biotechnology company’s ARGON-1 Phase 2a study of EDP-305 for the treatment of non-alcoholic steatohepatitis (NASH).
San Diego-based Conatus Pharmaceuticals indicated that the company is considering a sale as part of an exploration of strategic alternatives.
Novo Nordisk submitted the company’s oral semaglutide drug, a pill that management hopes will transform the diabetes market, for approval in the United States.
Bristol-Myers Squibb Company and Nordic Bioscience, a Danish company specializing in biomarker technologies, today announced a collaboration agreement to develop biomarker technology to potentially aid in the diagnosis and monitoring of fibrotic diseases including non-alcoholic steatohepatitis (NASH).
Akarna Therapeutics Ltd. announced that it has been acquired by Allergan plc. Allergan obtains rights to AKN-083, Akarna’s lead product candidate for the potential treatment of non-alcoholic steatohepatitis (NASH) and other liver diseases.
